Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome

Alina Dulau-Florea, Raul C. Braylan, Yanna Ding, Nisha Patel, Katherine Calvo, Elizabeth Hill, Emma M. Groarke, Neal S. Young, Bhavisha A. Patel

Blood (2023) 142 (Supplement 1): 4681.

https://doi.org/10.1182/blood-2023-186736

Published: 2023

Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Blood (2023) 142 (Supplement 1): 337.

https://doi.org/10.1182/blood-2023-181811

Published: 2023

Journal Articles

Eltrombopag Can Stimulate Trilineage Hematopoiesis with Transfusion Independence in Patients with Refractory Severe Aplastic Anemia: Results From a Phase II Trial

Matthew J. Olnes, MD, PhD, Phillip Scheinberg, MD, Katherine Calvo, MD, PhD, Yong Tang, Susan Soto, RN, Xingmin Feng, PhD, Ronan G. Desmond, MD, MRCP, FRCPath, Jay N. Lozier, M.D., Ph.D., Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2011) 118 (21): 54.

https://doi.org/10.1182/blood.V118.21.54.54

Published: 2011

Journal Articles

Hevylite™ Assays Detect a Hidden Immunoparesis Associated with Adverse Biology in Myeloma Precursor Disease: A Prospective Clinical Study

Rene Costello, Karina Espana, Neha Korde, MD, Mary Kwok, MD, Adriana Zingone, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Irina Maric, MD, Katherine Calvo, MD, PhD, Prashant Ramesh Tembhare, MD, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 5065.

https://doi.org/10.1182/blood.V118.21.5065.5065

Published: 2011

Journal Articles

CD81: A Novel, Specific and Highly Sensitive Marker in Flow Cytometric Diagnosis of Plasma Cell Dyscrasia

Prashant Ramesh Tembhare, MD, Constance Yuan, MD, PhD, Neha Korde, MD, Irina Maric, MD, Katherine Calvo, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Ola Landgren, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD

Blood (2011) 118 (21): 2880.

https://doi.org/10.1182/blood.V118.21.2880.2880

Published: 2011

Journal Articles

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Adriana Zingone, MD, PhD, Neha Korde, MD, Jinqiu Chen, PhD, Liqiang Xi, MD, Mark Raffeld, MD, Beata Holkova, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, Austin Doyle, MD, Irina Maric, MD, Katherine Calvo, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Christina Annunziata, MD, PhD, Steven Grant, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 306.

https://doi.org/10.1182/blood.V118.21.306.306

Published: 2011

Journal Articles

A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma

Neha Korde, MD, Jane Trepel, Mattias Carlsten, MD Ph.D, Adriana Zingone, MD, PhD, Rene Costello, Mary Ann Yancey, RN, Marcia Mulquin, RN, Irina Maric, MD, Katherine Calvo, MD, PhD, Prashant Ramesh Tembhare, MD, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Min-Jung Lee, MD, Sylvia Alarcon, George Carter, PA, Richard Childs, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 2944.

https://doi.org/10.1182/blood.V118.21.2944.2944

Published: 2011

NARROW

Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Eltrombopag Can Stimulate Trilineage Hematopoiesis with Transfusion Independence in Patients with Refractory Severe Aplastic Anemia: Results From a Phase II Trial

Hevylite™ Assays Detect a Hidden Immunoparesis Associated with Adverse Biology in Myeloma Precursor Disease: A Prospective Clinical Study

CD81: A Novel, Specific and Highly Sensitive Marker in Flow Cytometric Diagnosis of Plasma Cell Dyscrasia

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Eltrombopag Can Stimulate Trilineage Hematopoiesis with Transfusion Independence in Patients with Refractory Severe Aplastic Anemia: Results From a Phase II Trial

Hevylite™ Assays Detect a Hidden Immunoparesis Associated with Adverse Biology in Myeloma Precursor Disease: A Prospective Clinical Study

CD81: A Novel, Specific and Highly Sensitive Marker in Flow Cytometric Diagnosis of Plasma Cell Dyscrasia

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only